Foldrx Pharmaceuticals

Add To Watchlist
General Information
Company Name
Foldrx Pharmaceuticals
Founded Year
2003
Location (Offices)
Founders / Decision Makers
Christine Bulawa - Senior Director, Research
Number of Employees
3
Industries
Biotechnology, Health Care
Funding Stage
Series Unknown
Social Media

Foldrx Pharmaceuticals - Company Profile

FoldRx Pharmaceuticals is a biotechnology and healthcare company founded in 2003. The company focuses on developing first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding. The last investment of $29.00M was made in a Venture Round on 15 June 2010. The investors in this round included F-Prime Capital, Novartis Venture Fund, Alta Partners, HealthCare Ventures, Morgenthaler Ventures, TPG, and Novo Ventures. The company's focus on addressing the underlying causes of protein misfolding-related diseases sets it apart in the biotechnology and healthcare industries, reflecting potential for future growth and impact

Taxonomy: pharmaceuticals, drug development, disease-modifying, small molecule therapeutics, protein misfolding, cellular function, protein maintenance, misfolded proteins, mutations, quality control mechanisms, toxic intermediates

Funding Rounds & Investors of Foldrx Pharmaceuticals (3)

View All
Funding Stage Amount No. Investors Investors Date
Venture Round $29.00M 7
F-Prime Capital, investor in Foldrx Pharmaceuticals's Venture Round round Novartis Venture Fund, investor in Foldrx Pharmaceuticals's Venture Round round Alta Partners, investor in Foldrx Pharmaceuticals's Venture Round round HealthCare Ventures, investor in Foldrx Pharmaceuticals's Venture Round round Morgenthaler Ventures, investor in Foldrx Pharmaceuticals's Venture Round round
TPG, Novo Ventures 		15 Jun 2010
Series B $43.00M 3
F-Prime Capital, investor in Foldrx Pharmaceuticals's Series B round Novartis Venture Fund, investor in Foldrx Pharmaceuticals's Series B round Original Investors, investor in Foldrx Pharmaceuticals's Series B round
30 May 2006
Series A $16.00M - 01 Jan 2004

Latest News of Foldrx Pharmaceuticals

View All

No recent news or press coverage available for Foldrx Pharmaceuticals.

Similar Companies to Foldrx Pharmaceuticals

View All
InFlectis BioScience - Similar company to Foldrx Pharmaceuticals
InFlectis BioScience Harnessing expertise in cellular defense and drug discovery to develop molecules targeting misfolded protein disorders
Glycotope GmbH - Similar company to Foldrx Pharmaceuticals
Glycotope GmbH Improving the lives of cancer patients by enabling treatment options that go beyond today’s standard of care
Tierra Biosciences - Similar company to Foldrx Pharmaceuticals
Tierra Biosciences Speed, scale, and simplicity with protein on-demand
Glycomine Inc. - Similar company to Foldrx Pharmaceuticals
Glycomine Inc. We are developing GLM101, a novel substrate replacement therapy for PMM2-CDG, a congenital disorder of glycosylation.
Nuclera - Similar company to Foldrx Pharmaceuticals
Nuclera Bring rapid protein access to your benchtop with eProtein Discovery
Circle Decoration Circle Decoration

Want to dive deeper into Foldrx Pharmaceuticals? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now